Best of GU & GI 2020

The Best of GU & GI Cancers Summit Canada 2020 is a full day event being held April 17th, 2020 at The Westin Prince Hotel in Toronto, Ontario.

The focus of this meeting will be to provide medical oncologists with a summary of the most significant treatment advances in Genitourinary and Gastrointestinal malignancies presented at major international events in 2019 and 2020. The Best of GU & GI Cancers Summit faculty will draw from some of Canada’s most influential oncologists.

Learning Objectives:

1. To discuss pivotal trials and research presented in the different disease sites.

2. To review the current standard of care for key malignancies.

3. To discuss the current controversies in the management of specific GU & GI cancers.

REGISTRATION FEES:

Conference Chairs

Dr. Scott Berry, BSc, MD, MHSc, FRCPC

Dr. Scott Berry is a medical oncologist and Professor and Department Head in the Queen's University Department of Oncology.  He is the Cancer Program Medical Director at the Cancer Centre of Southeastern Ontario at the Kingston Health Sciences Centre.

Dr. Berry is an active participant in clinical research in GI cancer. He is the Co-Chair of the GI Disease Site Group of the CCO Program in Evidence Based Care. 

Dr. Berry loves teaching, has won several teaching awards and is a past Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology 

His other academic interest is the bioethical issues surrounding the care of people with cancer, in particular the ethical issues surrounding funding new and expensive cancer medications. Dr. Berry has a Master’s degree in Bioethics from the University of Toronto. He is the former ethics advisor to the pan-Canadian Oncology Drug Review and has served on the ASCO Ethics Committee.

Areas of specialization: Colorectal cancer, GI cancers, medical education, bioethics of cancer care

Dr. Kala Sridhar, MD, MSc, FRCPC

Dr. Kala Sridhar is an Associate Professor within the Department of Medicine, Division of Medical Oncology at the University of Toronto. She is head of the genitourinary cancers medical oncology site group at the Princess Margaret Hospital and treats primarily bladder, prostate and kidney cancers.

She has an active research program in the area of bladder cancer, evaluating new therapies and imaging modalities; and is currently the international study chair of a National Cancer Institute of Canada (NCIC) phase 2 clinical trial. In 2011, she was recognized for her teaching excellence with a University of Toronto teaching award.

Other Information

For more information, please contact Stefania Capelo, at stefania@oncologyeducation.com